How to Store Urolithin A: Stability and Handling, Per the Research

What Urolithin A Is — and Why That Changes the Storage Question

Urolithin A is a gut-microbial metabolite of ellagitannins and ellagic acid, a small phenolic molecule rather than a peptide or protein. That distinction matters for any storage discussion, because most of the handling conventions circulating in research-chemical communities — reconstitution with bacteriostatic water, cold-chain shipping, worry about peptide bond hydrolysis — were developed for lyophilized peptides. Urolithin A has no peptide backbone to hydrolyse and no tertiary structure to denature. Its chemistry is that of a dibenzo[b,d]pyran-6-one with free hydroxyl groups, which is a different stability profile entirely: phenolics are generally more vulnerable to oxidation, light and alkaline conditions than to the degradation routes that dominate peptide science.

The compound itself has been studied across a wide range of biological models. Researchers reported that Urolithin A improved mitochondrial health, reduced cartilage degeneration and alleviated pain in osteoarthritis models (PMID 35778837), and a separate study reported that it attenuated memory impairment and neuroinflammation in APP/PS1 mice (PMID 30871577). Those are pharmacology papers, not stability papers — a distinction this page returns to repeatedly.

Compound-Specific Data vs. General Stability Science

An honest storage page has to separate two categories of information, because they carry very different weight:

• Compound-specific findings: statements traceable to published Urolithin A research. In the literature surveyed here, these describe biological activity and, in a few cases, formulation strategy — not shelf-life testing, not accelerated stability studies, and not degradation kinetics.
• General stability science: well-established principles for handling solid organic reference materials, lyophilised powders and organic-solvent stock solutions. These principles are widely used in laboratories, but they are not Urolithin A measurements and should never be presented as if a study had tested them on this molecule.

Everything below is labelled as one or the other. Where a claim carries a PubMed link, it comes from that paper. Where it does not, it is general laboratory practice offered as context only.

Refrigeration: Solid Material vs. Prepared Solutions

Solid, dry material

General stability science, not Urolithin A-specific data. Dry solids are the most stable form of almost any small organic compound, because the two reagents that drive most degradation — water and dissolved oxygen — are largely absent. Standard practice for phenolic reference materials is storage in a tightly sealed, opaque or amber container, protected from humidity, with refrigerated or freezer conditions used to slow oxidative and photolytic processes further. Ambient-temperature storage of a sealed dry solid is common in analytical laboratories, with cold storage treated as an additional margin rather than a strict requirement.

The practical complication with refrigerated solids is condensation. When a cold, sealed vial is opened in a warm room, moisture condenses on the material and can seed hydrolytic or oxidative pathways that the dry state had suppressed. Laboratory convention is therefore to allow sealed containers to equilibrate to room temperature before opening — a general handling principle that applies across dry powders, lyophilised peptides and crystalline small molecules alike.

Prepared solutions

General stability science, with one compound-specific note. Urolithin A is poorly soluble in water, which is why cell-culture and animal work typically relies on organic co-solvents such as DMSO, or on formulation approaches that improve dispersion. Once a phenolic compound is in solution, stability generally drops sharply relative to the solid state: dissolved oxygen, pH drift, light exposure and repeated warming all have access to the molecule. The standard laboratory response is short-dated aliquots kept frozen, shielded from light, and discarded rather than repeatedly reopened.

The compound-specific note is that researchers have gone to considerable lengths to stabilise and localise Urolithin A delivery rather than rely on simple solutions. One study described mitochondrial-oriented injectable hydrogel microspheres used to maintain homeostasis of chondrocyte metabolism in osteoarthritis (PMID 38274127), which illustrates that formulation — not just refrigeration — is how delivery problems with this molecule have been approached experimentally.

Shelf Life and Expiry Dating

General stability science. Expiry dating on a research material and expiry dating on an approved drug product are different things. Pharmaceutical expiry dates derive from formal stability programmes under defined temperature and humidity conditions, with assays confirming that potency and impurity limits hold across the stated period. Research-grade materials frequently carry a "retest date" instead, meaning the material is re-assayed rather than automatically discarded. A date printed on a container therefore describes the conditions the manufacturer tested, not a universal property of the molecule.

No published Urolithin A shelf-life study appears among the papers cited on this page. The literature here is mechanistic and pharmacological — for example, one study reported that Urolithin A modulated PER2 degradation via SIRT1 and enhanced the amplitude of circadian clocks in human senescent cells (PMID 39796454) — and none of it substitutes for a certificate of analysis or a documented stability programme.

Room Temperature and Travel

General stability science. The variables that matter during transport are cumulative heat exposure, light, humidity and mechanical disturbance. For sealed dry solids, brief ambient excursions are generally considered low-risk; the same is not assumed for solutions, which are the fragile form. Cabin versus hold placement, ambient temperature at layovers and the duration of exposure are the practical determinants, and none of them have been characterised for Urolithin A in the studies cited here.

Regulatory framing is also worth separating from stability framing. Urolithin A appears in the research literature as an investigational compound and in commerce in some jurisdictions as an ingredient subject to food or supplement rules; research-use-only material is not intended for human use regardless of how well it is stored. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, and treat regulatory classification questions as legal questions rather than stability questions.

Freezing and Freeze–Thaw Cycles

General stability science. Freezing is the default long-term condition for stock solutions of small organic molecules, typically at −20 °C for working stocks and colder for archival material. Two cautions are standard. First, DMSO freezes near room temperature and is hygroscopic, so frozen DMSO stocks accumulate water each time a container is opened in humid air — water uptake, not the cold itself, is the usual cause of drift. Second, repeated freeze–thaw cycling exposes a solution to condensation, concentration gradients at the ice front and additional dissolved oxygen, which is why single-use aliquots are preferred over one repeatedly cycled vial.

For dry solids, freezing is generally regarded as unnecessary but harmless if the container is genuinely moisture-tight and warmed before opening. Lyophilised-peptide guidance often recommends freezer storage as the default; that recommendation is specific to peptide chemistry and is offered here only as an analogy, not as a Urolithin A finding.

Comparison of physical forms

Signs of Degradation: What Studies Report

No degradation-signature study for Urolithin A appears in the verified literature used on this page, so nothing below is presented as a measured finding for this compound. General stability science holds that oxidised phenolics commonly darken or yellow, that caking and clumping in a powder indicate moisture uptake, and that precipitate, cloudiness or colour change in a previously clear solution are visual cues that something has changed chemically. Visual inspection detects only gross changes; analytical assay — HPLC purity, for instance — is the only way degradation is actually quantified, which is why certificates of analysis matter more than appearance.

What the published work does report is biological activity in material that was characterised and handled under each study's own methods. Researchers reported that Urolithin A promoted atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in apolipoprotein E-deficient mice (PMID 38886550), that it attenuated doxorubicin-induced cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1 (PMID 39725191), and that it protected chondrocytes from mechanical overloading-induced injuries (PMID 34220525). Those results describe biology, not shelf life.

Why the Mechanistic Literature Still Matters Here

Storage is ultimately about preserving whatever property a study measured. In the Urolithin A literature that property is usually mitophagy-related signalling. One study reported that mitophagy curtailed cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging (PMID 38280852), and another reported that Urolithin A inhibited breast cancer progression via activating TFEB-mediated mitophagy in tumour macrophages (PMID 38615740). Related work reported that Urolithin A promoted the degradation of TMSB10 to deform F-actin in non-small-cell lung cancer models (PMID 39368341). The broader mitophagy field continues to expand around this axis, including work reporting that HUWE1 targeted mitochondria via RMC1 to promote neurodevelopment (PMID 42490384) and work reporting that deoxycholic acid impaired mitochondrial fitness and suppressed mitophagy through Parkin ubiquitination in colorectal cancer models (PMID 42520384). None of these papers tested storage conditions; each simply used material prepared to its own stated specification.

Reading a Storage Claim Critically

1. Ask whether the source measured this molecule. A stability figure quoted for lyophilised peptides is not a Urolithin A figure.
2. Ask what form was tested. Solid-state and solution-state stability differ by orders of magnitude for many phenolics.
3. Ask what "expiry" meant. A retest date, a manufacturer's tested window and a pharmaceutical expiry date are three different claims.
4. Ask whether appearance was the only endpoint. Colour and clarity are screening cues; assay data are measurement.

Related Reading

• Urolithin A: what the research covers
• Peptide storage and stability, per the literature

References

• Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis (Aging Cell, 2022)
• Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice (Journal of Neuroinflammation, 2019)
• Mitochondrial-Oriented Injectable Hydrogel Microspheres Maintain Homeostasis of Chondrocyte Metabolism to Promote Subcellular Therapy in Osteoarthritis (Research, 2024)
• Urolithin A Modulates PER2 Degradation via SIRT1 and Enhances the Amplitude of Circadian Clocks in Human Senescent Cells (Nutrients, 2024)
• Urolithin A promotes atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in Apolipoprotein E-deficient mice (Acta Pharmacologica Sinica, 2024)
• Urolithin A attenuates Doxorubicin-induced cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1 (Chemico-Biological Interactions, 2025)
• Urolithin A Protects Chondrocytes From Mechanical Overloading-Induced Injuries (Frontiers in Pharmacology, 2021)
• Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging (Nature Communications, 2024)
• Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages (Journal of Advanced Research, 2025)
• Urolithin A promotes the degradation of TMSB10 to deformation F-actin in non-small-cell lung cancer (Phytomedicine, 2024)
• HUWE1 targets mitochondria via RMC1 to promote neurodevelopment (PNAS, 2026)
• Deoxycholic acid impairs mitochondrial fitness and suppresses mitophagy through Parkin ubiquitination driving CD8+ T cell Exhaustion in Colorectal Cancer (Redox Biology, 2026)